Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs
Z Xia, J Zheng, L Zheng, E Zheng, Z Zou… - Lipids in Health and …, 2021 - Springer
Background The prevalence of dyslipidemia in China is increasing annually. Current studies
suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies …
suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies …
Association of Dyslipidemia With Nucleoside Analogue Treatment in HBeAg-Positive Chronic Hepatitis B Patients
Z Xia, J Zheng, L Zheng, E Zheng, Z Zou, X Sheng… - 2021 - researchsquare.com
Background The prevalence of dyslipidemia in China is increasing annually. Current studies
suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies …
suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies …